Mediator Kinase Inhibition Sensitizes AML Models to Venetoclax

A peer-reviewed Leukemia paper published online November 11 identifies CDK8/19 Mediator kinase inhibition as an AML vulnerability and reports preclinical synergy with venetoclax. It does not establish patient efficacy.




